ClinicalTrials.gg
CompletedNCT00335244Updated Feb 2, 2015

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery

A Phase 3 interventional study of L-citrulline and Placebo of intravenous L-citrulline in Heart Defects, Congenital and Hypertension, Pulmonary, sponsored by Asklepion Pharmaceuticals, LLC. Completed at 1 site in United States. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2015-02-02.

Sponsored by Asklepion Pharmaceuticals, LLC · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 356 studies in Heart Defects, Congenital with a site in United States — 66 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.

Enrollment
68th of 184
77 · median 50
Started
2006
with 15 others
Phase 3
19 of 356
2 open now
Registered
38th of 356
by date

Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 68th largest by enrollment of the 184 interventional ones that give a count, is one of 16 that started in 2006, is one of 19 in phase 3, and was the 38th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

66 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Heart Defects, Congenital with a site in United States, or all of them as a file.
02

Study summary

This clinical trial will determine the safety and effectiveness of intravenous L-citrulline in children undergoing cardiopulmonary bypass during heart surgery. Participants will be randomly assigned to either L-citrulline or a placebo (a substance that has no medicine in it).

Citrulline is a protein building block in the body that can convert into another substance, nitric oxide (NO), which controls blood pressure in the lungs. Increased blood pressure in the lungs can be an important surgical problem; it may also lead to problems following surgery, such as severe high blood pressure in the lungs (pulmonary hypertension), increased time spent on a breathing machine, and a longer stay in the intensive care unit (ICU). The hypothesis of this study is that perioperative supplementation with intravenous citrulline will increase plasma citrulline, arginine and NO metabolites and prevent elevations in the postoperative PVT leading to a decrease in the duration of postoperative invasive mechanical ventilation.

Read the detailed description

Increased pulmonary vascular tone (PVT) can complicate the postoperative course of the following five surgical procedures for congenital heart defects: 1) unrestrictive ventricular septal defect (VSD) repair; 2) atrioventricular septal (AVSD) repair; 3) arterial switch procedure for transposition of the great arteries (TGA); 4) bidirectional Glenn shunt procedure; and 5) Fontan procedure for single ventricle lesions. PVT is partially controlled by NO. Arginine, the precursor to NO, is a product of the urea cycle. Preliminary data have been presented regarding 169 infants and children who have undergone one of six previous surgical procedures. It was found that urea cycle function and plasma arginine levels were significantly decreased in all participants. Furthermore, participants with increased PVT had significantly lower arginine levels compared to participants with normal PVT. Finally, a genetic single nucleotide polymorphism (SNP) in the rate limiting urea cycle enzyme (carbamyl phosphate synthetase I [CPSl T1405N]) appeared to affect postoperative plasma arginine levels and PVT. The hypothesis is that genetic polymorphisms in the rate limiting urea cycle enzyme CPSl, and other important enzymes in the urea cycle, influence the availability of NO precursors. It is further hypothesized that perioperative enhancement of urea cycle function with the key urea cycle intermediate (citrulline) will increase plasma arginine and NO metabolites and prevent elevations in PVT.

03

Conditions studied

  • Heart Defects, Congenital
  • Hypertension, Pulmonary
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing cardiopulmonary bypass surgery with 1 of the following 5 procedures:

    1. AVSD repair
    2. VSD repair
    3. Bidirectional Glenn
    4. Modified Fontan
    5. Arterial switch

Exclusion criteria

Exclusion Criteria:

  • Pulmonary artery or vein abnormalities not being addressed surgically
  • Preoperative requirement for mechanical ventilation or intravenous inotrope support
  • Any condition that might interfere with study objectives, as determined by the investigator
  • Pregnant
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    1

    Intravenous L-citrulline

    Drug: L-citrulline

  • Placebo comparator
    2

    Placebo of intravenous L-citrulline

    Drug: Placebo of intravenous L-citrulline

Interventions

  • 150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU

  • DrugPlacebo of intravenous L-citrulline

    Placebo of intravenous L-citrulline

06

What researchers measure

Primary outcomes

  1. Duration of postoperative mechanical ventilation in hours compared between treatment groups.

    Time frame: Measured in hours from the end of surgery until extubation

Secondary outcomes

  1. Incidence of increased PVT (defined as a sustained mean pulmonary artery pressure greater than 20 mm Hg for at least 2 hours, measured during the first 48 hours

    Time frame: Measured in hours from the end of surgery until extubation

  2. Postoperative intravenous inotrope score

    Time frame: Measured at 48 hours

  3. Length and volume of chest tube drainage

    Time frame: Measured in hours from the end of surgery until removal of chest tubes

  4. Length of ICU stay

    Time frame: Measured in hours from the end of surgery to discharge from ICU

  5. Length of hospitalization

    Time frame: Measured from the day of surgery until discharge from hospital

  6. Survival

    Time frame: Measured at 30 days post surgical repair

07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2006
First posted
Jun 9, 2006
Start
May 2006
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results delay requested
May 21, 2013
Last update
Feb 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00335244
Lead sponsor
Asklepion Pharmaceuticals, LLC
Responsible party
Sponsor
First posted
Jun 9, 2006
Start date
May 2006
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Feb 2, 2015

Study contacts

Fredrick E. Barr, MD, MSCI
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Citrulline

Start the discussion